205 related articles for article (PubMed ID: 37086892)
1. Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
Karlowsky JA; Lob SH; Khan TK; Chen WT; Woo PCY; Seto WH; Ip M; Leung SWM; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2023 Jun; 33():260-266. PubMed ID: 37086892
[TBL] [Abstract][Full Text] [Related]
2. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
[No Abstract] [Full Text] [Related]
3. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF
Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
Karlowsky JA; Lob SH; Chen WT; DeRyke CA; Siddiqui F; Young K; Motyl MR; Sahm DF
Int J Antimicrob Agents; 2023 Sep; 62(3):106900. PubMed ID: 37354921
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.
Karlowsky JA; Lob SH; Siddiqui F; Polis T; Vallejo JL; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Jun; 6(3):dlae077. PubMed ID: 38799180
[TBL] [Abstract][Full Text] [Related]
6. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and
Karlowsky JA; Lob SH; Hawser SP; Kothari N; Siddiqui F; Alekseeva I; DeRyke CA; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2023 Aug; 5(4):dlad098. PubMed ID: 37577157
[TBL] [Abstract][Full Text] [Related]
7. Imipenem-Relebactam Susceptibility in
Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
[TBL] [Abstract][Full Text] [Related]
8.
Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36763081
[No Abstract] [Full Text] [Related]
9. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021.
Wise MG; Karlowsky JA; Chen WT; Siddiqui F; Young K; Motyl MR; Sahm DF
J Formos Med Assoc; 2024 Mar; 123(3):400-407. PubMed ID: 37735013
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Lob SH; Kazmierczak KM; Chen WT; Siddiqui F; DeRyke CA; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2022 Jun; 29():527-533. PubMed ID: 34896336
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
[TBL] [Abstract][Full Text] [Related]
12.
Karlowsky JA; Lob SH; DeRyke CA; Hilbert DW; Wong MT; Young K; Siddiqui F; Motyl MR; Sahm DF
Antimicrob Agents Chemother; 2022 May; 66(5):e0018922. PubMed ID: 35491836
[TBL] [Abstract][Full Text] [Related]
13. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
Shortridge D; Kantro V; Castanheira M
Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
[TBL] [Abstract][Full Text] [Related]
14. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
[TBL] [Abstract][Full Text] [Related]
15.
Wise MG; Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
Microb Drug Resist; 2023 Aug; 29(8):360-370. PubMed ID: 37253158
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
Lee YL; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
[TBL] [Abstract][Full Text] [Related]
17.
Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
[TBL] [Abstract][Full Text] [Related]
18. Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020.
Hilbert DW; DeRyke CA; Motyl M; Hackel M; Young K
BMC Microbiol; 2023 Jun; 23(1):165. PubMed ID: 37312049
[TBL] [Abstract][Full Text] [Related]
19. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21.
Karlowsky JA; Lob SH; Bauer KA; Esterly J; Siddiqui F; Young K; Motyl MR; Sahm DF
JAC Antimicrob Resist; 2024 Feb; 6(1):dlad152. PubMed ID: 38222461
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
